Get your patients started with ORLADEYO® (berotralstat)

Switching patients should be based on their clinical condition and your discretion1

These recommendations are from the manufacturer of ORLADEYO and have not been evaluated in a controlled clinical study.

ORLADEYO™ switch considerations summary for HCPs ORLADEYO™ switch considerations summary for HCPs

Dosing recommendations

  • The recommended dosage of ORLADEYO is one 150 mg capsule taken orally once daily with food2
    • For certain patient populations, the recommended dosage is one 110 mg capsule taken orally once daily with food2

Other considerations

  • Ensure patients have rescue therapy available for treatment of breakthrough hereditary angioedema (HAE) attacks2
  • Patients should not take additional doses of ORLADEYO to treat an acute attack of HAE; the safety and effectiveness of ORLADEYO as a rescue treatment for HAE attacks have not been established2
  • GI reactions may occur in patients receiving ORLADEYO. If GI reactions persist, a reduced dosage of 110 mg once daily with food may be considered2